Clinical trial
Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
NCT00303732 · Daniel George, MD, Other · Completed
Key facts
| NCT number | NCT00303732 |
|---|---|
| Title | Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors |
| Official title | PTK787/ZK222584 and RAD001 for Patients With Advanced Solid Tumors |
| Acronym | PTK/RAD |
| Lead sponsor | Daniel George, MD, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Kidney Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | RAD001 (everolimus), PTK787 (vatalanib) |
| Enrollment | 37 |
| Start date | Dec 1, 2004 |
| Primary completion | Aug 1, 2010 |
| Completion | Aug 1, 2012 |
| First posted | Mar 17, 2006 |
| Last update posted | Mar 3, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: